Merck和ChemLex将探索AI和自动化合作,促进更快、更有效率的药物和材料开发。 Merck and ChemLex to explore AI and automation collaboration for faster, more efficient drug and material development.

Merck与ChemLex签署了一份不具约束力的谅解备忘录,以探讨以推进自动化化学和AI驱动合成为重点的协作。 Merck and ChemLex have signed a non-binding Memorandum of Understanding to explore a collaboration focused on advancing automated chemistry and AI-driven synthesis. 该伙伴关系旨在通过将Merck的科学知识与ChemLex的自动化平台结合起来,提高生命科学和电子学早期研究的速度、效率和可复制性。 The partnership aims to enhance the speed, efficiency, and reproducibility of early-stage research in life sciences and electronics by combining Merck’s scientific expertise with ChemLex’s automated platform. 关键领域包括自动化合成、反应优化和高通量实验,初步努力针对高影响方案。 Key areas include automated synthesis, reaction optimization, and high-throughput experimentation, with initial efforts targeting high-impact programs. 两家公司都强调数据丰富、可扩展的创新和数字转型,并计划进一步讨论,以确定今后的步骤。 Both companies emphasize data-rich, scalable innovation and digital transformation, planning further discussions to define next steps.